https://www.selleckchem.com/pr....oducts/tc-s-7009.htm
Introduction Half of Crohn's disease patients develop stenosis around 20 years after the disease onset. For a long time, surgery has been the only therapeutic approach for strictures. The introduction of anti-TNFα could be revolutionary in the management of these patients due to their potential role in stenoses' treatment. The aim of our work was to summarize efficacy data of anti-TNFα drugs in stricturing CD patients.Areas covered Several case series and observational studies have shown that infliximab and adalimumab are effective in
Like
Comment
Share
